UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
report (date of earliest event reported): January 13, 2007
ZIOPHARM
Oncology, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-32353
|
84-1475642
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1180
Avenue of the Americas, 19th
Floor
New
York, NY 10036
(Address
of principal executive offices) (Zip Code)
(646)
214-0700
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
January 13, 2007, the Company entered into a one year agreement with Dr. Robert
Peter Gale pursuant to which Dr. Gale will serve in a consulting capacity as
Chief Scientific Advisor commencing January 15, 2007. Under this agreement,
the
Company will pay Dr. Gale $100,000 for advisory services rendered and will
pay
the cost of COBRA continuation coverage for Dr. Gale during the one year term
of
the agreement. The Company will also reimburse Dr. Gale for travel expenses
incurred in connection with his performance of these services.
Since
January 15, 2004, Dr. Gale has been employed as Senior Vice President Research
of the Company pursuant to an employment agreement with the Company that expired
January 14, 2007.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
99.1 |
Press
Release dated January 16, 2007.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| Date:
January 16, 2007 |
ZIOPHARM
Oncology, Inc.:
(REGISTRANT)
|
|
|
|
| |
By: |
/s/ Richard
E. Bagley |
| |
RICHARD
E. BAGLEY,
President, Chief
Operating
Officer and Chief Financial Officer
|
| |
|
Exhibit
Index
|
Exhibit
No.
|
|
Description
|
| |
|
|
|
99.1
|
|
Press
Release dated January 16, 2007
|